

[**Pramana joins Proscia Ready**](#)

written by CAP TODAY
March 11, 2024

March 11, 2024—Proscia announced that Pramana, an artificial intelligence-enabled health technology company, is now a Proscia Ready partner.



©2026 CAP TODAY, all rights reserved.

[**FDA clears Diasorin Liaison Plex system**](#)

written by CAP TODAY
March 11, 2024

March 5, 2024—Diasorin announced FDA 510(k) clearance for its Liaison Plex platform and Flex respiratory assay.



©2026 CAP TODAY, all rights reserved.

[**Sebia gets FDA clearance for free light chain assays**](#)

written by CAP TODAY
March 11, 2024

Sebia announced it has received FDA 510(k) clearance for its free light chain kappa and lambda assays, intended to aid in diagnosing and monitoring patients who have multiple myeloma or immunoglobulin light chain amyloidosis.



©2026 CAP TODAY, all rights reserved.

[Bruker to acquire EliTechGroup](#)

written by CAP TODAY
March 11, 2024

March 1, 2024—Bruker Corp. has entered into a definitive share purchase agreement to acquire EliTechGroup for €870 million (about \$940 million) in cash, excluding EliTech’s clinical chemistry business.



©2026 CAP TODAY, all rights reserved.

[Binx enters into distribution agreement with Cardinal Health](#)

written by CAP TODAY
March 11, 2024

Feb. 21 2024—Binx Health announced a national distribution agreement with Cardinal Health to expand access to care with its CLIA-waived, FDA-cleared Binx IO.

[Doing more, doing better in bladder cancer](#)

written by CAP TODAY
March 11, 2024

February 2024—From her vantage at the University of Texas MD Anderson Cancer Center, Donna Hansel, MD, PhD, has a clear view of cancer’s latest frontiers. Progress and breakthroughs are the norm. But even she sounds impressed when she surveys the changes in her specialty, urothelial cancer. “We are now thinking what we never before thought was possible: We are thinking about cures and lifelong remission from disease,” says Dr. Hansel, division head and professor of pathology and laboratory medicine. It’s been a long time coming, says Dr. Hansel, who is also the Dr. Eva Lotzova and Peter Lotz memorial research chair. The disease historically has been caught in a sort of prepositional triangle—underfunded, overlooked, and underdiagnosed—with serious consequences. For years, she says, “We thought bladder cancer had only one treatment”—BCG, or Bacillus Calmette-Guérin, therapy. Because the field lacked a large volume of research to propel better diagnostics and treatments, “people died of this disease because it progressed.”

[As AI use expands, ethics at the leading edge](#)

written by CAP TODAY
March 11, 2024

February 2024—Artificial intelligence is sizzling, so much so that *New Yorker* magazine, evoking the dazzling and the potentially devouring nature of AI technology, tagged 2023 as “The Year A.I. Ate the Internet.”

[Biomarker tests with discrepant results—why the differences?](#)

written by CAP TODAY
March 11, 2024

February 2024—When multimodality testing reveals discordant biomarker results, which method is correct? Annette S. Kim, MD, PhD, and JinJuan Yao, MD, PhD, in a CAP23 session last fall used their cases to share strategies for resolving discrepancies—or, in some cases, what *look* like discrepancies.

[With pipeline for pathologists, others lacking, eyes on AI](#)

written by CAP TODAY
March 11, 2024

February 2024—Artificial intelligence and Medicare Advantage contracts were at the center of the Jan. 2 Compass Group virtual roundtable led by CAP TODAY publisher Bob McGonnagle. “If you want to get into the AI world, there are many lanes you can swim in,” said Michael Feldman, MD, PhD, of Indiana University School of Medicine.

[How we can help pathologists in Ethiopia](#)

written by CAP TODAY
March 11, 2024

February 2024—Ethiopia’s health care system is at a crossroads as it grapples with the dual burden of infectious diseases and a surge in noncommunicable ailments.